Efficacy and safety of percutaneous computed tomography-guided microwave ablation for colorectal cancer, oligometastatic liver-only disease: a single center’s experience

Maria Tsitskari\textsuperscript{a}, Dimitris Filippiadis\textsuperscript{b}, Periklis Zavridis\textsuperscript{a}, Argyro Mazioti\textsuperscript{b}, Thomas Vrachliotis\textsuperscript{d}, Leonidas Alevizos\textsuperscript{c}, Elias Brountzos\textsuperscript{b}, Nikos Kelekis\textsuperscript{b}

American Medical Center, Nicosia, Cyprus; Attiko University General Hospital, Athens, Greece; Ammochostos General Hospital, Cyprus; Henry Ntynan Hospital Center, Greece

Abstract

**Background** We retrospectively evaluated the effectiveness and safety of computed tomography-guided percutaneous microwave ablation (MWA) of metastatic liver disease in terms of 5-year overall survival and 5-year disease-free survival.

**Methods** Institutional database research identified 32 colorectal cancer patients with oligometastatic liver-only disease who underwent percutaneous computed tomography-guided MWA. Contrast-enhanced computed tomography or magnetic resonance imaging was used for post-ablation follow up. Patient and tumor characteristics, MWA technique and complications were evaluated. In addition, the 5-year overall survival, the 5-year disease-free survival, and the potential factors affecting the survival of these patients were analyzed.

**Results** Mean patient age was 72 years (male: female 21:11). In total 58 lesions were treated in 45 ablation sessions. Average lesion size was 2 cm (range 0.8-3.9 cm). The primary tumor for the majority of patients was in the colon (n=27), while in 5 patients it was located in the rectum. The majority of patients had 1 liver metastasis (n=16), 11 patients had 2, 4 patients had 3, and 1 patient had 4. Primary local tumor control was achieved in 91.3% (53/58) of the ablated lesions. Overall survival at 1, 3 and 5 years was 96.8%, 68.7% and 34.3%, respectively.

**Conclusion** Computed tomography-guided percutaneous MWA for metastatic liver-only disease in oligometastatic patients is a feasible, safe and effective therapy with satisfactory long-term survival rates.

**Keywords** Colorectal cancer, microwave ablation, hepatic metastases

Ann Gastroenterol 2020; 33 (6): 1-7

Introduction

Colon cancer is a common clinical entity throughout the world. It is the most common cancer in Europe and the third most common worldwide [1,2]. For metastatic liver disease secondary to colorectal cancer, apart from systemic chemotherapy, additional therapeutic options include surgery and interventional oncology techniques, such as percutaneous thermal destruction of metastatic lesions, or loco-regional control of metastatic liver disease with intra-arterial therapies. Both local thermal ablation and loco-regional intra-arterial therapies have been incorporated into the toolkit of the recently published guidelines of the European Society for Medical Oncology for the treatment of metastatic colon cancer, as potential treatment options for patients with oligometastatic disease [3]. Patients with oligometastatic disease may undergo thermal ablation as monotherapy or in combination with surgical resection, either initially or after initiation of systemic chemotherapy; the goal is to achieve long-term disease control and potentially radical treatment without the need for ongoing systemic therapy [3].

Percutaneous microwave ablation (MWA) is a relatively new method of thermal catalysis growing in popularity because
of its potential advantages over radiofrequency ablation (RFA), which include, but are not limited to larger ablation zones in a shorter time frame, higher temperature profiles, and being less affected by the “heat-sink effect” and by tissue impedance [4].

The purpose of this study was to evaluate the efficacy and safety of percutaneous MWA in oligometastatic patients with colorectal cancer liver-only disease in clinical practice. In addition, the survival and the potential factors affecting the survival of these patients were analyzed.

Patients and methods

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected by a priori approval by the institution's human research committee.

Patients

Institutional database research identified 32 patients with metachronous hepatic metastases from colorectal cancer, treated with MWA between August 2012 and September 2018, who either were not surgical candidates (n=28) or refused surgery (n=4). All patients were referred for MWA by the oncology multidisciplinary team of our institution. The study’s inclusion criteria were oligometastatic colorectal cancer with liver-only metastatic disease (<5) and a maximum lesion diameter of 4 cm per lesion. Exclusion criteria were: the presence of extrahepatic metastases; coagulation disorders; clinical signs of liver failure, such as excessive ascites or encephalopathy; acute or advanced renal disease; and signs of acute infection. The diagnosis of metastatic liver disease was made using computed tomography (CT) or magnetic resonance imaging (MRI) scanning.

Procedure

All patients were informed in detail about the whole procedure, the potential risks and complications; all gave signed written consent. All MWA procedures were performed by 2 experienced interventional radiologists under CT guidance, using 2 different commercially available systems, AMICA (HS, Italy) and Emprint (Medronic, UK). Conscious sedation was administered to all patients during the procedure by an anesthesiologist.

MWA was always performed in an inpatient setting. CT guidance with sequential scanning (120 kV peak, 240 mAs wavelength and 2 mm slice thickness) was used for planning, targeting and intraprocedural modification during the ablation session. A combination of local anesthesia (performed by the interventional radiologist) and conscious sedation with fentanyl (delivered by the anesthesiologist) was used to treat intraprocedural pain. Under extended local sterility, MWA was performed via a percutaneous approach in all cases. After the initial CT scan, a skin entry point was selected. A microwave antenna was inserted to the lesion of interest and its approach was evaluated with sequential CT scans. Once the antenna was in the correct location, the ablation session was performed according to the guidelines provided by the manufacturer concerning quantity of energy (W), duration (min) and resultant ablation volume (cm). Whenever deemed necessary, the microwave antenna was repositioned and another ablation session was performed. The goal was to ablate the whole lesion, including a circumferential zone of surrounding normal liver parenchyma with minimum width 0.5 cm. CT was used to assess the ablation zone and potential immediate complications at the end of the ablation treatment. At the end of the procedure all patients were hospitalized for 1 day for hemodynamic monitoring and analgesia administration to control postprocedural pain.

Follow up

All patients were followed-up with liver CT or MRI scan. The same imaging method as in the preprocedural screening was selected. The follow-up protocol included imaging at 1, 3, 6 and 12 months after ablation and every 6 months thereafter. The presence of ovoid-like, non-enhancing lesions was considered to represent areas of necrosis. Primary local tumor control was defined as a lack of enhancement of the target tumor immediately after the procedure. Secondary local tumor control was defined as the absence of contrast enhancement after a repeated session. Complete necrosis was defined as the absence of contrast enhancement 3 months after the ablation. During the follow up, the ablated tumors were categorized into 2 groups according to the imaging findings: tumors with local tumor control (lack of enhancement of the ablation zone), and tumors with local tumor progression (appearance of new focal areas of enhancement within or in proximity to the ablation zone). The presence of new metastases was also recorded. In the event of local tumor progression or the presence of new metastases, patients were evaluated for a new MWA procedure, depending on the technical feasibility, the likelihood of achieving local tumor control, and the patient's overall condition.

Clinical endpoints and statistical analysis

The clinical endpoints of our study were the 5-year overall survival and 5-year disease-free survival for each patient, as well as the time to tumor progression (TTP) for each individual lesion. The TTP for each individual lesion was calculated from the date of MWA. The time to the appearance of new metastases was calculated from the date of MWA until the appearance of new metastases in any anatomical position other than the original ablation site. Overall survival was defined as the time from the first MWA until the time of death from the disease, or until the time of last contact with the patient. Patients who died of other causes were excluded from the statistical analysis.

Quantitative data were expressed as mean, median or range. Overall survival and disease-free survival analyses were performed using the Kaplan-Meier method with the log rank test. Cox proportional hazards analysis, which
estimates the odds ratio within 95% confidence intervals, was used to determine independent prognostic factors. Local tumor progression, new liver metastases and extrahepatic disease in the various subgroups of patients, determined by their clinicopathological variables, were compared using the chi-square test (Pearson, Mantel-Haenzel test for linear association), with Yates' correction or Fisher's exact test whenever needed. For all statistical tests, P-values of <0.05 were considered significant. The statistical analysis was performed using SPSS 18.0 (SPSS Inc, Chicago, Ill).

The definition of complications was assigned according to the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) classification system [5].

**Results**

In total, 32 patients (21 men, 11 women) with colorectal liver metastases, mean age 72 (±9.94) years, were included in our study. The primary tumor for the majority of patients was in the colon (n=27), while in 5 patients it was located in the rectum. Sixteen patients had 1 liver metastasis, 11 patients had 2, 4 patients had 3, and 1 patient had four metastasis Lesions from 0.8 cm up to 3.9 cm, with median diameter of 2 cm, were treated. Patients' demographics and clinicopathological characteristics are given in Table 1.

A total of 58 lesions were treated in 45 ablation sessions. In Fig. 1 we can see the example of a patient with a history of colorectal cancer and metachronous solitary hepatic lesion treated with MWA. Four of these lesions were new metastases that appeared during the follow-up period. Primary local tumor control was achieved in 91.3% (53/58) of the ablated lesions. In 5 patients MWA was considered incomplete and it was repeated within 24 h. Secondary local tumor control was achieved in 100% of the treated lesions. Complete necrosis was obtained in 49/58 (84.4%) of the ablated lesions. In relation to the size of the lesions, complete necrosis was seen in 35/38 (92%) metastases with diameter <2 cm, 12/16 (75%) metastases with diameter 2.1-3 cm and 2/4 (50%) metastases with diameter 3.1-4 cm.

Patients were followed-up over a period of 5 years. During the follow-up period, local tumor progression, as first sign of disease recurrence, was recorded in 8 patients (25%). In Fig. 2 we can see an example of one patient with rectal cancer and metachronous hepatic metastases, who had a recurrence 12 months after initial treatment with MWA. New hepatic metastases, as first sign of recurrence, were recorded in 19 patients (59.4%), while 40.6% of these patients also developed extrahepatic disease. Patients with at least one lesion greater than 2 cm in diameter developed new hepatic metastasis more often compared to those with lesions smaller than 2 cm at initial presentation (68.42% vs. 31.58%, P=0.04). Moreover, the total number of liver metastases at presentation predicted extrahepatic disease during the follow-up period, since patients with only 1 liver metastasis presented extrahepatic disease significantly less often compared to the rest of the population (15.58% vs. 84.42%, P=0.02).

Overall survival at 1, 3 and 5 years was 96.8%, 68.7% and 34.3%, respectively. Fourteen patients died of cancer, while 7 died of other reasons, including myocardial infarction, stroke and pulmonary embolism. Those 7 patients were excluded from the survival analysis. Of the patients still alive at their last follow-up visit, 54% (6/11) were disease-free.

Disease-free survival ranged between 3 and 60 months (mean 30, median: 15 months). In the univariate analysis, patients who had at least one liver metastasis greater than 2 cm in diameter (n=17) had worse 5-year disease-free survival compared to the rest of the group (20.06 vs. 40.64, P=0.04) (Table 2, Fig. 3); this finding was further confirmed in the multivariate analysis (Table 3).

Overall survival ranged between 11 and 60 months (mean: 42.64, median: 48 months). In the univariate analysis, a statistically significant difference in 5-year overall survival was recorded between patients who had 1 liver metastasis (n=13) and those who had more (n=12) (55.00 vs. 29.25, P=0.01) at initial presentation (Table 2, Fig. 4). This was also confirmed in the multivariate analysis (Table 3).

None of the remaining clinicopathological factors examined, including patients' age, sex and incomplete MWA, repeated 1 month later, was found to be associated with the clinical outcome defined by the overall and disease-free survival (Table 2).

Seven patients mentioned pain in the right hypochondrium, referring to the ipsilateral shoulder in a few of them. All these patients were treated with systemic oral analgesics and reported pain resolution less than 1 week after the procedure.

**Discussion**

Hepatic metastases occur in approximately 50% of patients with colorectal cancer [6-8]. Although surgical resection has

---

**Table 1 Patients' demographics and clinicopathological characteristics**

| Characteristics | Value |
|-----------------|-------|
| Age (years)     | 51-88 (70.96, 72.5, 9.94) |
| Tumor diameter (cm) | 0.8-3.9 (1.85, 1.85, 0.67) |

| Frequency | Percentage |
|-----------|------------|
| Sex       |            |
| Male      | 21         | 65.6       |
| Female    | 11         | 34.4       |
| Primary tumor |      |            |
| Colon     | 27         | 84.4       |
| Rectum    | 5          | 15.6       |
| Number of hepatic metastases |          |
| 1         | 16         | 50         |
| 2         | 11         | 34.4       |
| 3         | 4          | 12.5       |
| 4         | 1          | 3.1        |
| Diameter of metastases |        |
| ≤2 cm     | 15         | 46.9       |
| >2 cm     | 17         | 53.1       |

Data in parenthesis are expressed as mean, median, standard deviation

Number of patients who had at least 1 tumor greater or smaller than 2 cm

---

**Table 2 Disease-free survival of patients with colorectal hepatic metastases**

| Characteristics | Value |
|-----------------|-------|
| Age (years)     | 51-88 (70.96, 72.5, 9.94) |
| Tumor diameter (cm) | 0.8-3.9 (1.85, 1.85, 0.67) |

| Frequency | Percentage |
|-----------|------------|
| Sex       |            |
| Male      | 21         | 65.6       |
| Female    | 11         | 34.4       |
| Primary tumor |      |            |
| Colon     | 27         | 84.4       |
| Rectum    | 5          | 15.6       |
| Number of hepatic metastases |          |
| 1         | 16         | 50         |
| 2         | 11         | 34.4       |
| 3         | 4          | 12.5       |
| 4         | 1          | 3.1        |
| Diameter of metastases |        |
| ≤2 cm     | 15         | 46.9       |
| >2 cm     | 17         | 53.1       |

Data in parenthesis are expressed as mean, median, standard deviation

Number of patients who had at least 1 tumor greater or smaller than 2 cm

---

**Table 3 Multivariate analysis of patients with colorectal hepatic metastases**

| Characteristics | Value |
|-----------------|-------|
| Age (years)     | 51-88 (70.96, 72.5, 9.94) |
| Tumor diameter (cm) | 0.8-3.9 (1.85, 1.85, 0.67) |

| Frequency | Percentage |
|-----------|------------|
| Sex       |            |
| Male      | 21         | 65.6       |
| Female    | 11         | 34.4       |
| Primary tumor |      |            |
| Colon     | 27         | 84.4       |
| Rectum    | 5          | 15.6       |
| Number of hepatic metastases |          |
| 1         | 16         | 50         |
| 2         | 11         | 34.4       |
| 3         | 4          | 12.5       |
| 4         | 1          | 3.1        |
| Diameter of metastases |        |
| ≤2 cm     | 15         | 46.9       |
| >2 cm     | 17         | 53.1       |

Data in parenthesis are expressed as mean, median, standard deviation

Number of patients who had at least 1 tumor greater or smaller than 2 cm

---

**Fig. 1** Example of a patient with a history of colorectal cancer and metachronous hepatic lesion treated with MWA

**Fig. 2** Example of a patient with a history of colorectal cancer and metachronous hepatic lesion treated with MWA

**Fig. 3** Example of a patient with a history of colorectal cancer and metachronous hepatic lesion treated with MWA

**Fig. 4** Example of a patient with a history of colorectal cancer and metachronous hepatic lesion treated with MWA

---

**Annals of Gastroenterology 33**
historically been the mainstay of treatment, with the highest success rates and a 5-year survival rate ranging from 24-58%, more than 70% of patients are non-surgical candidates despite the recent advances and developments in surgical techniques [6-8]. Therefore, minimally invasive techniques of thermal ablation constitute an alternative method for the treatment of non-resectable hepatic metastases and are increasingly used to prolong the survival of patients with chemotherapy alone or without any intervention [9-12]. Clinical outcomes are promising, with 5-year survival rates of 24-44%, similar to those for surgical resection [13-15].

Percutaneous MWA is a relatively new method of thermal ablation that is growing in popularity because of its potential advantages over RFA. There are data in the literature that support the efficacy and safety of MWA for the treatment of liver metastases, but there are only few studies with long-term results [4].

Our study presents the results of a 5-year follow up of 32 patients with colorectal cancer metastases who underwent percutaneous MWA. The 3- and 5-year survival rates of our study population were 68.7% and 34.3%, respectively, and are similar to those reported in other studies with MWA [16-19]. Yoshiyuki Wada reported 3- and 5-year survival outcomes of 44.6% and 33.7%, respectively, in patients with at least 5
Microwave ablation in colorectal hepatic metastases

or more colorectal cancer metastases who underwent only MWA and chemotherapy, whereas the disease was considered non-resectable [16]. Similarly, Eng et al reported a 4-year overall survival of 35.2% in 33 patients who had metastatic colorectal cancer with a maximum lesion diameter of 5.5 cm, treated with intraoperative MWA [17]. Wang et al found a 78.65% 3-year survival rate in 115 patients with colorectal liver metastases treated with percutaneous MWA under ultrasound guidance [19]. Similar long-term survival rates have been reported in studies following RFA for the treatment of hepatic metastases from colorectal cancer [13,20,21]. Solbiati et al reported 3- and 5-year survival rates of 69% and

48%, respectively, similar to those in our study, in 99 patients with colorectal cancer metastases treated with RFA [14]. These rates are comparable to the 5-year survival rates after surgical resection (24-58%) [22-25]. Recently, the results of a meta-analysis were published comparing MWA with RFA for the treatment of hepatocellular carcinoma and liver metastases. The authors concluded that MWA is at least as safe and effective as RFA for treating liver cancer and demonstrated significantly lower rates of local tumor progression [26].

Table 2 Five-year overall and disease-free survival according to clinicopathological variables in 32 patients with liver metastases treated with microwave ablation

| Variable (n) | 5-year survival | 5-year DFS | P-value | P-value |
|--------------|-----------------|------------|---------|---------|
| Age ≤70 years (11) | 43.18 | 28.09 | 0.88 | 0.99 |
| Age >70 years (14) | 42.21 | 31.17 | 0.73 | 0.59 |
| Sex Male (17) | 42.11 | 40.64 | 0.12 | 0.04 |
| Sex Female (8) | 43.70 | 20.06 | 0.73 | 0.73 |
| Tumor diameter <2 cm (15) | 46.23 | 36.14 | 0.12 | 0.09 |
| Tumor diameter ≥2 cm (17) | 38.25 | 24.16 | 0.12 | 0.04 |
| Number of tumors =1 (13) | 55.00 | 36.14 | 0.01 | 0.09 |
| Number of tumors >1 (12) | 29.25 | 24.16 | 0.01 | 0.09 |
| Repeat MWA (at 1st month) | 50.33 | 29.00 | 0.94 | 0.85 |
| Repeat MWA No (22) | 41.59 | 30.11 | 0.94 | 0.85 |

DFS, disease-free survival; MWA, microwave ablation

Table 3 Multivariate analysis in patients who underwent MWA

| Variable | 5-year survival | 5-year disease-free survival |
|----------|-----------------|------------------------------|
|          | Hazard ratio (95%CI) | P-value | Hazard ratio (95%CI) | P-value |
| Age*     | 0.43 (0.12-1.55) | 0.19 | 0.50 (0.16-1.59) | 0.24 |
| Sex      | 0.53 (0.13-2.13) | 0.37 | 0.88 (0.30-2.55) | 0.81 |
| Tumor size** | 4.1 (1.66-20.44) | 0.08 | 3.03 (1.05-10.31) | 0.04 |
| Number of tumors³ | 24.02 (3.71-155.44) | 0.001 | 2.71 (0.87-8.45) | 0.08 |
| Repeated MWA | 1.86 (0.24-14.49) | 0.55 | 0.91 (0.16-5.26) | 0.92 |

MWA, microwave ablation; CI, confidence interval
*cut value 70 years
*cut value 2 cm
³cut value 1 tumor

Figure 3 Kaplan-Meier survival curve demonstrating significantly worse 5-year disease-free survival in patients who had at least 1 liver tumor greater than 2 cm in diameter at presentation

Figure 4 Kaplan-Meier survival curve demonstrating significantly worse 5-year overall survival in patients who had 2 or more liver metastases at presentation
Univariate and multivariate analysis showed that only the number of liver metastases, at the initial presentation, significantly affected patients’ overall survival. The 5-year overall survival rate was 55% for patients with a solitary hepatic metastasis, vs. 29.5% for patients with 2 or more hepatic metastases. In addition, the total number of liver metastases at presentation appeared to be a prognostic factor for extrahepatic disease during the follow up, as patients with solitary hepatic metastases developed extrahepatic metastases at a much lower rate (15.58%) than the rest of the study population (84.42%).

Several studies that evaluated data following surgical resection of hepatic metastases have concluded that the number of metastases (usually more than 3) was an independent predictor factor of tumor recurrence, with poorer long-term results according to multivariate analysis [27,28]. A study by Siperstein et al [29] showed a significant difference in overall median survival (27 vs. 17 months) in 234 patients, based on the presence of fewer or more than 3 metastases at initial presentation. Likewise, studies of thermal ablation with RF have shown better long-term outcomes in patients with smaller and fewer tumors.

The univariate and multivariate analysis of our data also revealed that patients with at least one liver metastasis >2 cm in maximum diameter had worse 5-year disease-free survival compared to patients with liver metastases <2 cm in maximum diameter (20% vs. 40%); however, the difference in these patients' overall survival was not statistically significant. The size of a tumor for ablation is a well-known predictor of local tumor recurrence, and many researchers claim it to be the major factor. Therefore, it can affect the disease-free survival. Mulier [30] published the results of a multivariate analysis of the factors affecting local recurrence after percutaneous and intraoperative RFA in 5224 hepatic tumors and showed that the rate of local recurrence was 16% and 3.6%, respectively, for tumors <3 cm in diameter, and 25.9% and 21.7%, respectively, for tumors from 3 cm to 5 cm in diameter. Likewise, in our study, the local recurrence rate was much higher for metastases >3 cm versus metastases <3 cm, as local recurrence was observed in 13% of metastases with a diameter <3 cm and in 50% of metastases with a diameter >3.1 cm. However, the literature does not support the size of liver metastases at baseline as a prognostic factor for new metastases.

In conclusion, we reported the long-term follow-up results, up to 5 years, of 32 patients with 58 liver metastases from colorectal cancer treated with percutaneous MWA. Our results are comparable to those of previous series of patients treated with percutaneous thermal ablation, and substantially similar to the results after surgical resection. These findings highlight the safety and efficacy of percutaneous MWA for the treatment of liver metastases from colorectal cancer and emphasize the usefulness of thermal ablation as an alternative treatment for the large number of patients who are not surgical candidates or refuse surgical resection and selectively in specific subgroups of patients with resectable disease.

**Summary Box**

**What is already known:**
- Hepatic metastases occur in approximately 50% of patients with colorectal cancer
- For colorectal cancer metastatic liver disease, apart from systemic chemotherapy, additional therapeutic options include surgery and interventional oncology techniques, such as percutaneous thermal destruction of metastatic lesions or loco-regional control of metastatic liver disease with intra-arterial therapies
- The efficacy, safety and long-term outcomes of percutaneous radiofrequency ablation for the treatment of colorectal liver metastases has been well demonstrated in the literature

**What the new findings are:**
- Computed tomography-guided percutaneous microwave ablation for metastatic liver-only disease in patients with colorectal cancer and oligometastatic disease is a feasible, safe and effective therapy with satisfactory long-term survival rates
- The number of liver metastases at initial presentation significantly affected patients’ overall survival
- The size of a tumor for ablation has been shown to be a predictor of local tumor recurrence and can affect disease-free survival

**References**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87-108.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:E359-E386.
3. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016;27:1386-1422.
4. Lubner MG, Brace CL, Hinshaw JL, Lee FT Jr. Microwave tumour ablation: mechanism of action, clinical results, and devices. *J Vasc Interv Radiol* 2010;21 (8 Suppl):S192-S203.
5. Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. *Cardiovasc Interv Radiol* 2017;40:1141-1146.
6. Van Cutsem E, Nordlinger B, Adam R, et al; European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. *Eur J Cancer* 2006;42:2212-2221.
7. Zorzi D, Mullen JT, Abdalla EK, et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. *J Gastrointest Surg* 2006;10:86-94.
8. Covey AM, Brown KT, Jarnagin WR, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. *Ann Surg* 2008;247:451-455.

9. Ruefs T, Punt C, Van Coevorden F, et al. EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCGS). Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). *Ann Oncol* 2012;23:2619-2626.

10. Tanis E, Nordlinger B, Mauer, M, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. *Eur J Cancer* 2014;50:912-919.

11. Nishiwada S, Ko S, Mukogawa T, et al. Comparison between percutaneous radiofrequency ablation and surgical hepatectomy focusing on local disease control rate for colorectal liver metastases. *Hepatogastroenterology* 2014;61:436-441.

12. Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE. Resection compared to laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. *J Gastrointest Surg* 2008;12:1967-1972.

13. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. *Eur Radiol* 2009;19:1206-1213.

14. Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. *Radiology* 2012;265:958-968.

15. Veltri A, Sacchettio P, Tosetti I, Pagano E, Fava C, Gandini G. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. *Cardiovasc Intervent Radiol* 2008;31:948-956.

16. Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitisu H. Efficacy of surgical treatment using microwave coagulo-necrotic therapy for unresectable multiple colorectal liver metastases. *Onco Targets Ther* 2016;9:937-943.

17. Eng OS, Tsang AT, Moore D, et al. Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience. *J Surg Oncol* 2015;111:410-413.

18. Groeschl RT, Pilgrim CH, Hanna EM, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. *Ann Surg* 2014;259:1195-1200.

19. Wang J, Liang P, Yu J, et al. Clinical outcome of ultrasound-guided percutaneous microwave ablation on colorectal liver metastases. *Oncol Lett* 2014;8:323-326.

20. Hammill CW, Billingsley KG, Cassera MA, Wolf RF, Ujiki MB, Hansen PD. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. *Ann Surg Oncol* 2011;18:1947-1954.

21. Van Tilborg AA, Meijerink MR, Sietes C, et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. *Br J Radiol* 2011;84:556-565.

22. Karanikolas PJ, Jarnagin WR, Gonen M, et al. Long-term outcomes following tumour ablation for treatment of bilateral colorectal liver metastases. *JAMA Surg* 2013;148:97-101.

23. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 2004;239:818-825.

24. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. *Ann Surg* 2002;235:759-766.

25. Fernandez FG, Drebin JA, Linehan DC, Dehdashi F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). *Ann Surg* 2004;240:438-447.

26. Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. *Onco Targets Ther* 2019;12:6407-6438.

27. Adam R, Frilling A, Elias D, et al; Liver MetSurvey Centres. Liver resection of colorectal metastases in elderly patients. *Br J Surg* 2010;97:366-376.

28. Fukuda Y, Saito Y, Kikuchi H, et al. Colorectal carcinoma with potentially resectable metastases: factors associated with the failure of curative schedule. *Gastroenterol Clin Biol* 2008;32:390-400.

29. Siperstein AE, Barber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. *Ann Surg* 2007;246:559-565.

30. Muller S, Ni Y, Jamart J, Ruefs T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. *Ann Surg* 2005;242:158-171.